Literature DB >> 22693973

Prevalence of diabetes mellitus and glucose metabolism disorders in the first degree relatives of type 2 diabetic patients.

A Karaman1, F Bayram, K Gundogan, M Ozsan, H Karaman, F Kelestimur.   

Abstract

BACKGROUND AND OBJECTIVES: We designed this study to observe the DM prevalence, insulin resistance, beta cell reserve and the interaction of these parameters in the first degree relatives of Type 2 diabetic patients in Turkish population.
METHODS: 125 subjects were included in the study. 25 subjects without the first degree diabetic relatives were selected as the control group; they were matched by age, BMI, socio-economical, cultural and environmental factors. (OGTT), (IVGTT), (GST), and (ITT), were performed on all subjects and controls.
RESULTS: 12 (9.6 %) DM and 23 (18. 4 %) impaired glucose tolerance (IGT) cases of 125 subjects were diagnosed according to OGTT results. The mean BMI of diabetic subjects was significantly higher than of controls and subjects with normal glucose tolerance (p<0.05). When compared to the control group, the mean AUCinsulin levels were significantly lower in diabetic subjects (p<0.05). To observe the correlation between HOMAIR and KITT values, a statistically significant correlation was found (p<0.05, r: 0.222). There was a deficiency in the C-peptide response to glucagon stimulation in diabetic relatives (p<0.05, F: 4.59 One Way ANOVA).
CONCLUSION: We demonstrated that the first degree relatives of Type 2 diabetic patients constitute a high risk group for DM, IGT and insulin resistance by using four different tests in Turkish population.The significant finding(s) of the study: We demonstrated a high prevalence of glucose metabolism disorders in the relatives of type 2 diabetic patients.This study adds our knowledge; insulin resistance and decreased beta cell reserve occur before diabetes mellitus begin in relatives (Tab. 5, Ref. 42).

Entities:  

Mesh:

Year:  2012        PMID: 22693973     DOI: 10.4149/bll_2012_082

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  6 in total

1.  Liquiritin attenuates advanced glycation end products-induced endothelial dysfunction via RAGE/NF-κB pathway in human umbilical vein endothelial cells.

Authors:  Xiaoyi Zhang; Yu Song; Xiaolin Han; Liang Feng; Rushang Wang; Minghua Zhang; Maomao Zhu; Xiaobin Jia; Shaoying Hu
Journal:  Mol Cell Biochem       Date:  2012-11-15       Impact factor: 3.396

2.  Association of hypertension status and cardiovascular risks with sympathovagal imbalance in first degree relatives of type 2 diabetics.

Authors:  Gopal Krushna Pal; Chandrasekaran Adithan; Tarun Kumar Dutta; Pravati Pal; Nivedita Nanda; Venugopal Lalitha; Avupati Naga Syamsunder
Journal:  J Diabetes Investig       Date:  2013-12-01       Impact factor: 4.232

Review 3.  Resveratrol in Treating Diabetes and Its Cardiovascular Complications: A Review of Its Mechanisms of Action.

Authors:  Meiming Su; Wenqi Zhao; Suowen Xu; Jianping Weng
Journal:  Antioxidants (Basel)       Date:  2022-05-30

4.  Sympathovagal imbalance contributes to prehypertension status and cardiovascular risks attributed by insulin resistance, inflammation, dyslipidemia and oxidative stress in first degree relatives of type 2 diabetics.

Authors:  Gopal Krushna Pal; Chandrasekaran Adithan; Palghat Hariharan Ananthanarayanan; Pravati Pal; Nivedita Nanda; Thiyagarajan Durgadevi; Venugopal Lalitha; Avupati Naga Syamsunder; Tarun Kumar Dutta
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

Review 5.  Profile of metabolic abnormalities seen in patients with type 2 diabetes mellitus and their first degree relatives with metabolic syndrome seen in Benin City, Edo state Nigeria.

Authors:  Stephen O Ogedengbe; Ignatius U Ezeani
Journal:  J Diabetes Metab Disord       Date:  2014-05-23

6.  Genetic polymorphism of the Nrf2 promoter region is associated with vitiligo risk in Han Chinese populations.

Authors:  Pu Song; Kai Li; Ling Liu; Xiaowen Wang; Zhe Jian; Weigang Zhang; Gang Wang; Chunying Li; Tianwen Gao
Journal:  J Cell Mol Med       Date:  2016-05-25       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.